研究园简易版
·
经典书籍
·
期刊文章
·
有原文
·
完整版(可多选筛选、搜索)
·
首页
搜索
2021 年 · Clinical Trials(临床试验)
130 篇,新的在前。点标题看作者和摘要。
回到 2021 年
Stopping rules for phase I clinical trials with dose expansion cohorts
· SMMR · 2021-12-24 · 在第 1 页
Accounting for unequal cluster sizes in designing cluster randomized trials to detect treatment effect heterogeneity
· SiM · 2021-12-19 · 在第 1 页
Minimum sample size calculations for external validation of a clinical prediction model with a time‐to‐event outcome
· SiM · 2021-12-16 · 在第 1 页
Leveraging historical data to optimize the number of covariates and their explained variance in the analysis of randomized clinical trials
· SMMR · 2021-12-13 · 在第 2 页
Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response
· SiM · 2021-12-09 · 在第 2 页
Allowing for stratification in sample size planning of two-arm trials with continuous or binary outcome: Overview and tutorial
· SMMR · 2021-12-08 · 在第 2 页
A class of two-sample nonparametric statistics for binary and time-to-event outcomes
· SMMR · 2021-12-06 · 在第 2 页
Impact of minimal sufficient balance, minimization, and stratified permuted blocks on bias and power in the estimation of treatment effect in sequential clinical trials with a binary endpoint
· SMMR · 2021-11-29 · 在第 3 页
Estimation of the Odds Ratio in a Proportional Odds Model with Censored Time-Lagged Outcome in a Randomized Clinical Trial
· Biometrics · 2021-11-26 · 在第 4 页
BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint
· SiM · 2021-11-25 · 在第 4 页
Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity
· SMMR · 2021-11-22 · 在第 4 页
Improving efficiency of inference in clinical trials with external control data
· Biometrics · 2021-11-22 · 在第 4 页
Model-Robust Inference for Clinical Trials that Improve Precision by Stratified Randomization and Covariate Adjustment
· JASA · 2021-11-17 · 在第 4 页
Assumption-Lean Analysis of Cluster Randomized Trials in Infectious Diseases for Intent-to-Treat Effects and Network Effects
· JASA · 2021-11-17 · 在第 5 页
Sample size considerations for stepped wedge designs with subclusters
· Biometrics · 2021-11-16 · 在第 5 页
M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect
· SiM · 2021-11-15 · 在第 5 页
Cancer immunotherapy trial design with random delayed treatment effect and cure rate
· SiM · 2021-11-15 · 在第 5 页
Inference in response‐adaptive clinical trials when the enrolled population varies over time
· Biometrics · 2021-11-10 · 在第 5 页
A matching procedure for sequential experiments that iteratively learns which covariates improve power
· Biometrics · 2021-11-10 · 在第 5 页
A group‐sequential randomized trial design utilizing supplemental trial data
· SiM · 2021-11-09 · 在第 5 页
Conditional information and inference in response‐adaptive allocation designs
· SiM · 2021-11-08 · 在第 5 页
Optimal adaptive allocation using deep reinforcement learning in a dose‐response study
· SiM · 2021-11-07 · 在第 5 页
A Bayesian phase I/II platform design for co‐developing drug combination therapies for multiple indications
· SiM · 2021-11-03 · 在第 5 页
Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances
· SiM · 2021-10-27 · 在第 6 页
Regression-based causal inference with factorial experiments: estimands, model specifications and design-based properties
· Biometrika · 2021-10-25 · 在第 6 页
On the relative efficiency of the intent-to-treat Wilcoxon–Mann–Whitney test in the presence of noncompliance
· Biometrika · 2021-10-25 · 在第 6 页
Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers
· SiM · 2021-10-25 · 在第 6 页
Response‐adaptive treatment allocation for clinical studies with recurrent event and terminal event data
· SiM · 2021-10-24 · 在第 6 页
Set‐regression with applications to subgroup analysis
· SiM · 2021-10-20 · 在第 6 页
Propensity score methods for merging observational and experimental datasets
· SiM · 2021-10-20 · 在第 6 页
Estimating the sample mean and standard deviation from order statistics and sample size in meta-analysis
· SMMR · 2021-10-20 · 在第 6 页
A Novel Statistical Test for Treatment Differences in Clinical Trials Using a Response-Adaptive Forward-Looking Gittins Index Rule
· Biometrics · 2021-10-20 · 在第 6 页
Ratio estimators of intervention effects on event rates in cluster randomized trials
· SiM · 2021-10-15 · 在第 7 页
Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics
· SMMR · 2021-10-12 · 在第 7 页
The asymptotic distribution of the Net Benefit estimator in presence of right-censoring
· SMMR · 2021-10-11 · 在第 7 页
Developing clinical prediction models when adhering to minimum sample size recommendations: The importance of quantifying bootstrap variability in tuning parameters and predictive performance
· SMMR · 2021-10-08 · 在第 7 页
Existence and uniqueness of the Kronecker covariance MLE
· AoS · 2021-10-01 · 在第 8 页
A comparison of methods for analyzing a binary composite endpoint with partially observed components in randomized controlled trials
· SiM · 2021-09-29 · 在第 8 页
Interim monitoring in sequential multiple assignment randomized trials
· Biometrics · 2021-09-27 · 在第 8 页
Inference for the treatment effect in longitudinal cluster randomized trials when treatment effect heterogeneity is ignored
· SMMR · 2021-09-27 · 在第 8 页
Estimation of separable direct and indirect effects in continuous time
· Biometrics · 2021-09-27 · 在第 8 页
Power calculation for analyses of cross‐sectional stepped‐wedge cluster randomized trials with binary outcomes via generalized estimating equations
· SiM · 2021-09-23 · 在第 9 页
Use of the likelihood reduction factor in a path analysis framework to quantify surrogacy in clinical trials
· SiM · 2021-09-21 · 在第 9 页
Identification and inference for subgroups with differential treatment efficacy from randomized controlled trials with survival outcomes through multiple testing
· SiM · 2021-09-20 · 在第 9 页
Elastic priors to dynamically borrow information from historical data in clinical trials
· Biometrics · 2021-09-20 · 在第 9 页
A Bayesian approach for event predictions in clinical trials with time‐to‐event outcomes
· SiM · 2021-09-20 · 在第 9 页
Informing power and sample size calculations when using inverse probability of treatment weighting using the propensity score
· SiM · 2021-09-12 · 在第 10 页
Incorporating external data into the analysis of clinical trials via Bayesian additive regression trees
· SiM · 2021-09-07 · 在第 10 页
Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects
· Biometrics · 2021-09-07 · 在第 10 页
Sample sizes for cluster-randomised trials with continuous outcomes: Accounting for uncertainty in a single intra-cluster correlation estimate
· SMMR · 2021-09-03 · 在第 10 页
Sample size estimation for cancer randomized trials in the presence of heterogeneous populations
· Biometrics · 2021-09-03 · 在第 10 页
A bias correction method in meta‐analysis of randomized clinical trials with no adjustments for zero‐inflated outcomes
· SiM · 2021-09-03 · 在第 10 页
Quantifying the feasibility of shortening clinical trial duration using surrogate markers
· SiM · 2021-09-02 · 在第 10 页
Sample size re‐estimation in clinical trials
· SiM · 2021-08-25 · 在第 11 页
The statistical properties of RCTs and a proposal for shrinkage
· SiM · 2021-08-23 · 在第 11 页
When should matching be used in the design of cluster randomized trials?
· SiM · 2021-08-14 · 在第 11 页
Peter Krusche and Frank Bretz's Contribution to the Discussion of ‘Gaussian Differential Privacy’ by Dong et al
· JRSSB · 2021-08-03 · 在第 12 页
On the rate of convergence of fully connected deep neural network regression estimates
· AoS · 2021-08-01 · 在第 12 页
Optimal design of cluster randomized trials allowing unequal allocation of clusters and unequal cluster size between arms
· SiM · 2021-07-27 · 在第 13 页
Unit information prior for adaptive information borrowing from multiple historical datasets
· SiM · 2021-07-24 · 在第 13 页
Connecting Instrumental Variable methods for causal inference to the Estimand Framework
· SiM · 2021-07-21 · 在第 14 页
Sample size considerations for matched‐pair cluster randomization design with incomplete observations of binary outcomes
· SiM · 2021-07-09 · 在第 14 页
Precision Bayesian phase I‐II dose‐finding based on utilities tailored to prognostic subgroups
· SiM · 2021-07-09 · 在第 14 页
Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines
· SMMR · 2021-07-04 · 在第 15 页
Association of intracluster correlation measures with outcome prevalence for binary outcomes in cluster randomised trials
· SMMR · 2021-07-04 · 在第 15 页
Seamless phase I/II design for novel anticancer agents with competing disease progression
· SiM · 2021-07-02 · 在第 15 页
Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints
· SMMR · 2021-06-23 · 在第 15 页
Subgroup discovery in non‐inferiority trials
· SiM · 2021-06-22 · 在第 15 页
Sample size determination for stepped wedge cluster randomized trials in pragmatic settings
· SMMR · 2021-06-17 · 在第 16 页
Applications of simple and accessible methods for meta-analysis involving rare events: A simulation study
· SMMR · 2021-06-17 · 在第 16 页
Propensity‐score‐based meta‐analytic predictive prior for incorporating real‐world and historical data
· SiM · 2021-06-14 · 在第 16 页
Learning and confirming a class of treatment responders in clinical trials
· SiM · 2021-06-14 · 在第 16 页
A hypothesis test of feasibility for external pilot trials assessing recruitment, follow‐up, and adherence rates
· SiM · 2021-06-14 · 在第 16 页
Group sequential testing for cluster randomized trials with time‐to‐event endpoint
· Biometrics · 2021-06-13 · 在第 16 页
Exact sequential test for clinical trials and post‐market drug and vaccine safety surveillance with Poisson and binary data
· SiM · 2021-06-13 · 在第 16 页
Exploring consequences of simulation design for apparent performance of methods of meta-analysis
· SMMR · 2021-06-10 · 在第 16 页
A practical response adaptive block randomization (RABR) design with analytic type I error protection
· SiM · 2021-06-10 · 在第 16 页
Sample size formula for general win ratio analysis
· Biometrics · 2021-06-08 · 在第 16 页
Sample size adaptations and evaluation of pediatric study interpretability
· SiM · 2021-06-08 · 在第 16 页
Bridging preference‐based instrumental variable studies and cluster‐randomized encouragement experiments: Study design, noncompliance, and average cluster effect ratio
· Biometrics · 2021-06-08 · 在第 16 页
A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules
· SiM · 2021-06-07 · 在第 17 页
Frequentist rules for regulatory approval of subgroups in phase III trials: A fresh look at an old problem
· SMMR · 2021-06-02 · 在第 17 页
Bayesian phase II clinical trial design with noncompliance
· SiM · 2021-05-28 · 在第 18 页
Semiparametric regression analysis of partly interval‐censored failure time data with application to an AIDS clinical trial
· SiM · 2021-05-26 · 在第 18 页
Minimum sample size for external validation of a clinical prediction model with a binary outcome
· SiM · 2021-05-24 · 在第 18 页
Randomization‐based inference for a marginal treatment effect in stepped wedge cluster randomized trials
· SiM · 2021-05-21 · 在第 18 页
Feature screening with large‐scale and high‐dimensional survival data
· Biometrics · 2021-05-10 · 在第 19 页
Target estimands for efficient decision making: Response to comments on “Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study”
· SiM · 2021-05-08 · 在第 19 页
Contamination: How much can an individually randomized trial tolerate?
· SiM · 2021-05-07 · 在第 19 页
Bayesian adaptive design for clinical trials in Duchenne muscular dystrophy
· SiM · 2021-05-07 · 在第 19 页
Novel application of a discrete time‐to‐event model for randomized oral immunotherapy clinical trials with repeat food challenges
· SiM · 2021-05-06 · 在第 19 页
Design of phase III trials with long‐term survival outcomes based on short‐term binary results
· SiM · 2021-05-03 · 在第 20 页
Sequential knockoffs for continuous and categorical predictors: With application to a large psoriatic arthritis clinical trial pool
· SiM · 2021-04-25 · 在第 20 页
Estimation of required sample size for external validation of risk models for binary outcomes
· SMMR · 2021-04-21 · 在第 21 页
Semiparametric recurrent event vs time‐to‐first‐event analyses in randomized trials: Estimands and model misspecification
· SiM · 2021-04-20 · 在第 21 页
Cost‐efficient clinical studies with continuous time survival outcomes
· SiM · 2021-04-13 · 在第 21 页
Bayesian semiparametricmeta‐analytic‐predictiveprior for historical control borrowing in clinical trials
· SiM · 2021-04-13 · 在第 21 页
Early completion of phase I cancer clinical trials with Bayesian optimal interval design
· SiM · 2021-04-12 · 在第 22 页
Sample size estimation for modified Poisson analysis of cluster randomized trials with a binary outcome
· SMMR · 2021-04-07 · 在第 22 页
Prior Sample Size Extensions for Assessing Prior Impact and Prior-Likelihood Discordance
· JRSSB · 2021-04-05 · 在第 22 页
A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards
· SMMR · 2021-04-05 · 在第 22 页
Combined assessment of early and late‐phase outcomes in orphan drug development
· SiM · 2021-04-04 · 在第 22 页
Fusion designs and estimators for treatment effects
· SiM · 2021-03-29 · 在第 23 页
Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS)
· SiM · 2021-03-26 · 在第 23 页
Optimal planning of adaptive two‐stage designs
· SiM · 2021-03-18 · 在第 24 页
Sample size re‐estimation for covariate‐adaptive randomized clinical trials
· SiM · 2021-03-17 · 在第 24 页
Bayesian design and analysis of external pilot trials for complex interventions
· SiM · 2021-03-17 · 在第 24 页
On the design and the analysis of stratified biomarker trials in the presence of measurement error
· SiM · 2021-03-16 · 在第 24 页
Estimation of treatment effect in 2‐in‐1 adaptive design and some of its extensions
· SiM · 2021-03-15 · 在第 24 页
Optimal and ethical designs for hypothesis testing in multi‐arm exponential trials
· SiM · 2021-03-09 · 在第 24 页
Nonparametric machine learning for precision medicine with longitudinal clinical trials and Bayesian additive regression trees with mixed models
· SiM · 2021-03-09 · 在第 24 页
uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials
· SiM · 2021-03-02 · 在第 25 页
cLRT‐Mod: An efficient methodology for pharmacometric model‐based analysis of longitudinal phase II dose finding studies under model uncertainty
· SiM · 2021-03-02 · 在第 25 页
Recruitment prediction for multicenter clinical trials based on a hierarchical Poisson–gamma model: Asymptotic analysis and improved intervals
· Biometrics · 2021-03-02 · 在第 25 页
Comparative poisson clinical trials of multiple experimental treatments vs a single control using the negative multinomial distribution
· SiM · 2021-03-02 · 在第 25 页
On information fraction for Fleming‐Harrington type weighted log‐rank tests in a group‐sequential clinical trial design
· SiM · 2021-02-24 · 在第 25 页
Predicting study duration in clinical trials with a time‐to‐event endpoint
· SiM · 2021-02-12 · 在第 26 页
A novel estimand to adjust for rescue treatment in randomized clinical trials
· SiM · 2021-02-10 · 在第 26 页
Randomization‐based inference in the presence of selection bias
· SiM · 2021-02-09 · 在第 26 页
Power and sample size for multistate model analysis of longitudinal discrete outcomes in disease prevention trials
· SiM · 2021-02-07 · 在第 26 页
Hybrid design evaluating new biomarkers when there is an existing screening test
· SiM · 2021-02-04 · 在第 27 页
Two‐stage penalized regression screening to detect biomarker–treatment interactions in randomized clinical trials
· Biometrics · 2021-01-29 · 在第 28 页
Bridging across patient subgroups in phase I oncology trials that incorporate animal data
· SMMR · 2021-01-27 · 在第 28 页
A Bayesian‐bandit adaptive design for N‐of‐1 clinical trials
· SiM · 2021-01-18 · 在第 29 页
An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiency
· SMMR · 2021-01-17 · 在第 29 页
Information content of stepped wedge designs with unequal cluster‐period sizes in linear mixed models: Informing incomplete designs
· SiM · 2021-01-12 · 在第 29 页
The optimal design of clinical trials with potential biomarker effects: A novel computational approach
· SiM · 2021-01-11 · 在第 29 页
On Multi-Armed Bandit Designs for Dose-Finding Trials
· JMLR · 2021 · 在第 33 页
Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
· Biometrics · 2021 · 在第 36 页
Efficient odds ratio estimation under two‐phase sampling using error‐prone data from a multi‐national HIV research cohort
· Biometrics · 2021 · 在第 36 页